VTGN
Vistagen Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Vistagen Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Vistagen Therapeutics has 1 disclosed supplier and 3 disclosed customers in SEC filings.
SentenceWe have acquired our pherine product candidates from Pherin Pharmaceuticals, Inc. (Pherin), now our wholly-owned subsidiary, and Pherin undertook research and development of such product candidates prior to our acquisitions.
VTGN 10-Kaccession 0001628280-26-043271
SentenceAs of March 31, 2026, approximately $ 0.4 million of deferred revenue under the AffaMed Agreement remained to be recognized, which we expect to recognize in fiscal 2027.
VTGN 10-Kaccession 0001628280-26-043271
SentenceUnder the terms of the AffaMed Agreement, we received an upfront payment of $5.0 million in August 2020.
VTGN 10-Kaccession 0001628280-26-043271
SentenceApproximately $1.3 million of deferred revenue under the Negotiation Agreement with Fuji Pharma also remained as of March 31, 2026.
VTGN 10-Kaccession 0001628280-26-043271
Vistagen Therapeutics, Inc.
0.17
Largest filed tie
—
Expected move
No implied move.